Symptoms of Depression and Anxiety in Youth at Risk for Psychosis: A Systematic Review and Meta-Analysis
Poster B75, Tuesday, October%209, 11:30%20am%20-%201:00%20pm, Essex%20Ballroom
Daniel Devoe1, Megan Farris1, Jean Addington1; 1University of Calgary
Youth at clinical high risk (CHR) for psychosis often present with symptoms of depression and anxiety, which can reduce quality of life. Therefore, the aim of this systematic review was to determine the impact of all interventions on symptoms of depression and anxiety in CHR samples. We systematically searched Embase, EBM, PsycINFO, CINAHL, and MEDLINE. Studies were selected if they reported changes in depression or anxiety symptoms in youth at CHR and included an intervention. Data was evaluated using pairwise meta-analyses, stratified by time, and reported as the standardized mean difference (SMD). Twenty-three studies met our inclusion criteria, including a total of 1,831 CHR participants. The mean age was 19.35 years and 49% were female. Interventions included family therapy, glycine, antipsychotics, cognitive remediation, however analysis could only be performed on cognitive behavioural therapy (CBT) and omega-3. CBT did not significantly improve depression at 6-months (SMD=0.02; 95% CI=-0.25, 0.28), 12-months (SMD=-0.04; 95%CI= -0.23, 0.14), 18-months (SMD=-0.11; 95%CI=-0.41, 0.20), or at 24-48-month follow-up (SMD=-0.21; 95%CI= -0.50, 0.08). CBT did not significantly improve anxiety at 6-months (SMD=-0.10; 95% CI=-0.29, 0.08), 12-months (SMD=0.05; 95%CI= -0.14, 0.23), 18-months (SMD=0.09; 95%CI=-0.22, 0.39), or at 24-48-months (SMD=-0.06; 95%CI= -0.55, 0.43). Omega-3 did not significantly improve depression at 6-months (SMD=-0.46; 95CI=-1.15, 0.23) and 12-months (SMD=-0.29; 95%CI= -1.10, 0.51). In conclusion, no interventions significantly impacted symptoms of depression or anxiety in CHR samples. However, no trials in this review were designed to target and treat these symptoms and the CBT used was specifically designed to address attenuated psychotic symptoms.
Topic Area: Ultra High Risk / Prodromal Research